{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:59:42Z","timestamp":1790837982170,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.oret.2026.09.027","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:42:27Z","timestamp":1790689347000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Vascular Endothelial Growth Factor Injection-to-Surgery Interval in Diabetic Vitrectomy: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","author":[{"given":"Fahad R.","family":"Butt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-3215","authenticated-orcid":false,"given":"Salem Abu","family":"Al-Burak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7588-6541","authenticated-orcid":false,"given":"Fatima","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9808-038X","authenticated-orcid":false,"given":"Justin","family":"Shad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1525-7871","authenticated-orcid":false,"given":"Korolos","family":"Sawires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BScPharm; Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1607-8219","authenticated-orcid":false,"given":"Mohammed","family":"Alfalah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.oret.2026.09.027_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40135-019-00198-w","article-title":"Decision Making in Proliferative Diabetic Retinopathy Treatment","volume":"7","author":"Kansora","year":"2019","journal-title":"Curr Ophthalmol Rep"},{"issue":"6","key":"10.1016\/j.oret.2026.09.027_bib2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/ijms19061816","article-title":"Diabetic Retinopathy: Pathophysiology and Treatments","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oret.2026.09.027_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.963615","article-title":"The pathophysiological mechanisms underlying diabetic retinopathy","volume":"10","author":"Wei","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"10.1016\/j.oret.2026.09.027_bib4","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.oret.2026.09.027_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/eye.2014.13","article-title":"A review of anti-VEGF agents for proliferative diabetic retinopathy","volume":"28","author":"Osaadon","year":"2014","journal-title":"Eye (Lond)"},{"issue":"5","key":"10.1016\/j.oret.2026.09.027_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0161-6420(83)34526-7","article-title":"Complications of vitreous surgery for diabetic retinopathy. I. Intraoperative complications","volume":"90","author":"Oyakawa","year":"1983","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.oret.2026.09.027_bib7","first-page":"31","article-title":"Vitrectomy surgery of diabetic retinopathy complications","volume":"60","author":"Br\u0103ni\u015fteanu","year":"2016","journal-title":"Rom J Ophthalmol"},{"issue":"8","key":"10.1016\/j.oret.2026.09.027_bib8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bjophthalmol-2017-311344","article-title":"Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials","volume":"102","author":"Zhao","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.oret.2026.09.027_bib9","article-title":"Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.oret.2026.09.027_bib10","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.18240\/ijo.2022.10.09","article-title":"Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients","volume":"15","author":"Xu","year":"2022","journal-title":"Int J Ophthalmol"},{"issue":"4","key":"10.1016\/j.oret.2026.09.027_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/eye.2014.329","article-title":"Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model","volume":"29","author":"Park","year":"2015","journal-title":"Eye (Lond)"},{"issue":"11","key":"10.1016\/j.oret.2026.09.027_bib12","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/jcm8111960","article-title":"Incidence and Risk Factors for Tractional Macular Detachment after Anti-Vascular Endothelial Growth Factor Agent Pretreatment before Vitrectomy for Complicated Proliferative Diabetic Retinopathy","volume":"8","author":"Russo","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.oret.2026.09.027_bib13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.oret.2025.12.019","article-title":"Timing of preoperative anti-VEGF for vitrectomy in proliferative diabetic retinopathy: a competing-risks analysis of a large cohort","volume":"10","author":"Zhan","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.09.027_bib14","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2026.09.027_bib15","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2026.09.027_bib16","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.oret.2026.09.027_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.oret.2026.09.027_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ajo.2008.04.028","article-title":"Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy","volume":"146","author":"Yang","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.oret.2026.09.027_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00417-008-0774-y","article-title":"Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)","volume":"246","author":"Rizzo","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.oret.2026.09.027_bib20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/112067210901900526","article-title":"Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy","volume":"19","author":"Modarres","year":"2009","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"10.1016\/j.oret.2026.09.027_bib21","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/IAE.0b013e3181a8eb88","article-title":"Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin)","volume":"29","author":"Lo","year":"2009","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.oret.2026.09.027_bib22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/IAE.0b013e3181a3b7ef","article-title":"Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy","volume":"29","author":"Yeh","year":"2009","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.oret.2026.09.027_bib23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/IAE.0b013e3181c70168","article-title":"Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy","volume":"30","author":"Hattori","year":"2010","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.oret.2026.09.027_bib24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/112067211002000604","article-title":"Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy","volume":"20","author":"Hern\u00e1ndez-Da Mota","year":"2010","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.oret.2026.09.027_bib25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1755-3768.2008.01498.x","article-title":"Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment","volume":"88","author":"Yeung","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.oret.2026.09.027_bib26","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/IAE.0b013e31820a68e5","article-title":"Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage","volume":"31","author":"Farahvash","year":"2011","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.oret.2026.09.027_bib27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/eye.2011.149","article-title":"Bevacizumab prior to vitrectomy for diabetic traction retinal detachment","volume":"25","author":"Pokroy","year":"2011","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.oret.2026.09.027_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10792-012-9541-5","article-title":"Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab","volume":"32","author":"Gupta","year":"2012","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.oret.2026.09.027_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4137\/OED.S12352","article-title":"Effect of bevacizumab injection before vitrectomy on intravitreal hemorrhage in pseudophakic patients with proliferative diabetic retinopathy","volume":"5","author":"Demir","year":"2013","journal-title":"Ophthalmol Eye Dis"},{"issue":"11","key":"10.1016\/j.oret.2026.09.027_bib30","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/eye.2013.182","article-title":"Bevacizumab as an adjunct to vitreoretinal surgery for diabetic retinopathy in East Africa","volume":"27","author":"Guthrie","year":"2013","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.oret.2026.09.027_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/0974-9233.106387","article-title":"Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy","volume":"20","author":"Sato","year":"2013","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"6","key":"10.1016\/j.oret.2026.09.027_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3928\/23258160-20141118-06","article-title":"A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy","volume":"45","author":"Pakzad-Vaezi","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"10.1016\/j.oret.2026.09.027_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/08820538.2013.835847","article-title":"The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage","volume":"30","author":"Berk","year":"2015","journal-title":"Semin Ophthalmol"},{"issue":"4","key":"10.1016\/j.oret.2026.09.027_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.sjopt.2016.10.001","article-title":"The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy","volume":"30","author":"Al-Kharashi","year":"2016","journal-title":"Saudi J Ophthalmol"},{"key":"10.1016\/j.oret.2026.09.027_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2473234","article-title":"A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy","volume":"2016","author":"Yang","year":"2016","journal-title":"J Ophthalmol"},{"issue":"9","key":"10.1016\/j.oret.2026.09.027_bib36","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/eye.2017.75","article-title":"Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study)","volume":"31","author":"Comyn","year":"2017","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.oret.2026.09.027_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000493640","article-title":"Preoperative timing of intravitreal bevacizumab injection for proliferative diabetic retinopathy patients","volume":"60","author":"Feng","year":"2018","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.oret.2026.09.027_bib38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajo.2019.05.007","article-title":"Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: a prospective randomized clinical trial","volume":"207","author":"Arevalo","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.oret.2026.09.027_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/jop.2018.0093","article-title":"Conbercept and ranibizumab pretreatments in vitrectomy with silicone oil infusion for severe diabetic retinopathy","volume":"35","author":"Yang","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.oret.2026.09.027_bib40","first-page":"1740","article-title":"Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial","volume":"103","author":"Aleman","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.oret.2026.09.027_bib41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12886-019-1179-x","article-title":"Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab","volume":"19","author":"Hu","year":"2019","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"10.1016\/j.oret.2026.09.027_bib42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s13300-020-00822-0","article-title":"Ranibizumab pretreatment in vitrectomy with internal limiting membrane peeling on diabetic macular edema in severe proliferative diabetic retinopathy","volume":"11","author":"Guan","year":"2020","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.oret.2026.09.027_bib43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.21037\/apm.2020.01.10","article-title":"Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy","volume":"9","author":"Chen","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"1","key":"10.1016\/j.oret.2026.09.027_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/1874364102115010137","article-title":"Anti-vascular endothelial growth factor therapy as an adjunct to diabetic vitrectomy","volume":"15","author":"Karimov","year":"2021","journal-title":"Open Ophthalmol J"},{"key":"10.1016\/j.oret.2026.09.027_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1067670","article-title":"Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: a randomized controlled trial","volume":"10","author":"Qu","year":"2023","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.oret.2026.09.027_bib46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12886-022-02303-3","article-title":"The efficacy and safety of intravitreal injection of ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage","volume":"22","author":"Li","year":"2022","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"10.1016\/j.oret.2026.09.027_bib47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/jpm13040572","article-title":"Effect of intravitreal conbercept injection on complications of pars plana vitrectomy in patients with proliferative diabetic retinopathy","volume":"13","author":"Ding","year":"2023","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.oret.2026.09.027_bib48","doi-asserted-by":"crossref","DOI":"10.5935\/0004-2749.2023-0001","article-title":"Preoperative co-application of bevacizumab and tissue plasminogen activator in vitrectomy for proliferative diabetic retinopathy","volume":"87","author":"Aras","year":"2024","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.oret.2026.09.027_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.oret.2026.09.027_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026004999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026004999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:42:30Z","timestamp":1790836950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026004999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"alternative-id":["S2468653026004999"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.09.027","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Vascular Endothelial Growth Factor Injection-to-Surgery Interval in Diabetic Vitrectomy: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}